[6-K] NeuroSense Therapeutics Ltd. Current Report (Foreign Issuer)
NeuroSense Therapeutics Ltd. submitted a Form 6‑K reporting that certain registration statements (Form S‑8 and multiple Form F‑3 filings) are incorporated by reference. The report attaches a Form of Securities Purchase Agreement dated September 4, 2025 between NeuroSense and the purchaser named on the signature pages, and a Press Release dated September 4, 2025. The filing is signed by Alon Ben‑Noon, Chief Executive Officer.
NeuroSense Therapeutics Ltd.은 Form 6‑K를 제출하여 특정 등록 진술서(Form S‑8 및 다수의 Form F‑3 제출)가 참조에 의해 통합되었다고 보고했습니다. 보고서는 2025년 9월 4일자 증권 매매 계약서의 양식을 NeuroSense와 서명 페이지에 이름이 있는 매수자 간의 계약으로 첨부하고, 2025년 9월 4일자 보도자료를 첨부합니다. 이 제출은 알론 벤‑노운 최고경영자(CEO)가 서명했습니다.
قدمت NeuroSense Therapeutics Ltd. النموذج 6-K مع تقرير يفيد بأن بعض بيانات التسجيل (النموذج S-8 والعديد من النماذج F-3) مدمجة بالمرجعية. يرفق التقرير نموذج اتفاق شراء الأوراق المالية المؤرخ 4 سبتمبر 2025 بين NeuroSense والمشتري المذكور في صفحات التوقيع، وبيان صحفي بتاريخ 4 سبتمبر 2025. تم توقيع الملف من قبل ألون بن-نون، الرئيس التنفيذي.
NeuroSense Therapeutics Ltd. 提交了一个 Form 6‑K,报告某些注册声明(Form S‑8 及多份 Form F‑3 提交)通过引用被并入。报告还附上一份 日期为 2025 年 9 月 4 日的证券购买协议模板,由 NeuroSense 与签字页所列的购买方之间签署,以及一份 日期为 2025 年 9 月 4 日的新闻稿。该文件由 Alon Ben‑Noon,首席执行官签署。
- Securities Purchase Agreement dated Sept 4, 2025 is disclosed, confirming a documented transaction
- Form S‑8 and multiple Form F‑3 registration statements are incorporated by reference, maintaining registration coverage
- Report includes a Press Release dated Sept 4, 2025 and is duly signed by Alon Ben‑Noon, CEO
- None.
Insights
TL;DR: The 6‑K discloses a Securities Purchase Agreement dated Sept 4, 2025, indicating a financing or secondary transaction has been executed.
The inclusion of a Form of Securities Purchase Agreement dated Sept 4, 2025 in the 6‑K is a clear, document‑level disclosure of a securities transaction involving NeuroSense and an identified purchaser.
This is material to investors because executed purchase agreements typically relate to capital raising, investor commitments, or transfer of securities; the filing confirms the agreement exists but does not disclose economic terms in this excerpt.
TL;DR: The company incorporated prior registration statements by reference and attached a press release, meeting disclosure and signature formalities.
Stating that Form S‑8 and several Form F‑3 filings are incorporated by reference ensures those registration statements apply to securities covered by this report.
The attached Press Release dated Sept 4, 2025 and the CEO signature satisfy current report presentation; however, the excerpt does not include the press release text or financial terms of the purchase agreement.
NeuroSense Therapeutics Ltd.은 Form 6‑K를 제출하여 특정 등록 진술서(Form S‑8 및 다수의 Form F‑3 제출)가 참조에 의해 통합되었다고 보고했습니다. 보고서는 2025년 9월 4일자 증권 매매 계약서의 양식을 NeuroSense와 서명 페이지에 이름이 있는 매수자 간의 계약으로 첨부하고, 2025년 9월 4일자 보도자료를 첨부합니다. 이 제출은 알론 벤‑노운 최고경영자(CEO)가 서명했습니다.